» Authors » Gary Blick

Gary Blick

Explore the profile of Gary Blick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 424
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider S, Blick G, Burke C, Ward D, Benson P, Felizarta F, et al.
Infect Dis Ther . 2024 Apr; 13(4):891-906. PMID: 38570443
Introduction: Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) indicated for HIV-1. DTG/3TC is approved for antiretroviral therapy (ART)-naive people with HIV-1 and virologically suppressed individuals...
2.
Kabra M, Barber T, Allavena C, Marcelin A, Di Giambenedetto S, Pasquau J, et al.
Open Forum Infect Dis . 2023 Nov; 10(11):ofad526. PMID: 38033982
Background: To investigate the impact of the M184V/I mutation on virologic response to dolutegravir plus lamivudine (DTG + 3TC) in suppressed-switch populations, a meta-analysis was performed using virologic outcomes from...
3.
Evans J, Laking G, Strother M, Wang T, Metcalfe S, Blick G, et al.
Semin Oncol . 2017 Jan; 43(6):625-637. PMID: 28061980
Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the...
4.
Ramallo J, Kidder T, Albritton T, Blick G, Pachankis J, Grandelski V, et al.
AIDS Educ Prev . 2015 Aug; 27(4):298-311. PMID: 26241381
Social networking technologies are influential among men who have sex with men (MSM) and may be an important strategy for HIV prevention. We conducted focus groups with HIV positive and...
5.
Sulkowski M, Eron J, Wyles D, Trinh R, Lalezari J, Wang C, et al.
JAMA . 2015 Feb; 313(12):1223-31. PMID: 25706092
Importance: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities,...
6.
Eron J, Lalezari J, Slim J, Gathe J, Ruane P, Wang C, et al.
J Int AIDS Soc . 2014 Nov; 17(4 Suppl 3):19500. PMID: 25394009
Objective: Whether concomitant HIV antiretroviral therapy (ART) affects the safety and efficacy of interferon-free HCV therapies or whether HCV treatment may negatively affect HIV control is unclear. We assessed the...
7.
Akil B, Blick G, Hagins D, Ramgopal M, Richmond G, Samuel R, et al.
Antivir Ther . 2014 Oct; 20(3):343-8. PMID: 25321146
Background: The Phase III VIKING-3 study demonstrated that dolutegravir (DTG) 50 mg twice daily was efficacious in antiretroviral therapy (ART)-experienced subjects harbouring raltegravir- and/or elvitegravir-resistant HIV-1. VIKING-4 (ING116529) included a...
8.
Blick G
Postgrad Med . 2013 Jul; 125(2):30-9. PMID: 23816769
Objectives: To determine the incidence of hypogonadism in men with human immunodeficiency virus (HIV)/acquired immunodeficiency virus (AIDS), the most useful serum testosterone measurement and threshold for diagnosing hypogonadism, and the...
9.
Blick G, Khera M, Bhattacharya R, Kushner H, Miner M
Postgrad Med . 2013 Jul; 125(2):19-29. PMID: 23816768
Background: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), testosterone levels after testosterone replacement therapy (TRT) in this population have not been reported. Methods:...
10.
Miner M, Bhattacharya R, Blick G, Kushner H, Khera M
Postgrad Med . 2013 Jul; 125(2):8-18. PMID: 23816767
Background: Testosterone decline becomes more prevalent as men age and symptomatic testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding...